Nika Pharmaceuticals, Inc (NIKA) EBITDA (2021 - 2023)
Nika Pharmaceuticals' (NIKA) quarterly EBITDA came in at -$10143.0 in Q3 2023, down 60.01% YoY from -$25363.5 in Q3 2022, and up 63.52% on a QoQ basis from -$27806.0 in Q2 2023.
Nika Pharmaceuticals, Inc (NIKA) EBITDA (2021 - 2023) Analysis & Trends
Nika Pharmaceuticals (NIKA) has 3 years of EBITDA data on file, last reported at -$10143.0 in Q3 2023.
- Quarterly EBITDA fell 60.01% year-over-year to -$10143.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$33429.0 (up 98.94% YoY) and the FY2022 annual result came in at -$3.2 million, down 21540.26% from the prior year.
- EBITDA climbed to -$10143.0 in Q3 2023, from -$27806.0 in the prior quarter.
- In the past five years, EBITDA ranged from a high of $19570.0 in Q1 2023 to a low of -$3.2 million in Q2 2022.
- A 3-year average of -$291288.5 and a median of -$5754.0 in 2021 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA tumbled 106557.99% — and 2023, when it soared 209.85%.
- Tracing NIKA's EBITDA over 3 years: stood at -$3300.0 in 2021, then sank by 356.06% to -$15050.0 in 2022, then jumped by 32.6% to -$10143.0 in 2023.
- The last three EBITDA figures came in at -$10143.0 (Q3 2023), -$27806.0 (Q2 2023), and $19570.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -10,143.00 |
| Jun 30, 2023 | -27,806.00 |
| Mar 31, 2023 | 19,570.00 |
| Dec 31, 2022 | -15,050.00 |
| Sep 30, 2022 | -6,339.00 |
| Jun 30, 2022 | -3.16 Mn |
| Mar 31, 2022 | 6,316.00 |
| Dec 31, 2021 | -3,300.00 |
| Sep 30, 2021 | -2,699.00 |
| Jun 30, 2021 | -2,959.00 |
| Mar 31, 2021 | -5,754.00 |